THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

HIV infection and placental malaria reduce maternal transfer of multiple antimalarial antibodies in Mozambican women

Citation for published version:

Alonso, S, Vidal, M, Ruiz-Olalla, G, González, R, Jairoce, C, Manaca, MN, Vázquez-Santiago, M, Balcells, R, Vala, A, Ruperez, M, Cisteró, P, Fuente-Soro, L, Angov, E, Coppel, RL, Gamain, B, Cavanagh, D, Beeson, JG, Nhacolo, A, Sevene, E, Aponte, JJ, Macete, E, Aguilar, R, Mayor, A, Menéndez, C, Dobaño, C & Moncunill, G 2021, 'HIV infection and placental malaria reduce maternal transfer of multiple antimalarial antibodies in Mozambican women', *Journal of Infection*, vol. 82, no. 4, pp. 45-57.
<https://doi.org/10.1016/j.jinf.2021.02.024>

Digital Object Identifier (DOI):

[10.1016/j.jinf.2021.02.024](https://doi.org/10.1016/j.jinf.2021.02.024)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Journal of Infection

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

HIV infection and placental malaria reduce maternal transfer of multiple antimalarial antibodies in Mozambican women

Selena Alonso¹, Marta Vidal¹⁺, Gemma Ruiz-Olalla¹⁺, Raquel González^{1,2}, Chenjerai Jairoce², M. Nelia Manaca², Miquel Vázquez-Santiago¹, Reyes Balcells^{1,2}, Anifa Vala², María Ruperez^{1,2,4}, Pau Cisteró¹, Laura Fuente-Soro^{1,2}, Evelina Angov⁵, Ross L. Coppel⁶, Benoit Gamain⁷, David Cavanagh⁸, James G. Beeson⁹, Arsenio Nhacolo², Esperança Sevens^{2,3}, John J. Aponte^{1,2}, Eusébio Macete², Ruth Aguilar¹, Alfredo Mayor^{1,2}, Clara Menéndez^{1,2}, Carlota Dobaño^{1,2*#}, Gemma Moncunill^{1,2*#}

¹ISGlobal, Hospital Clínic - Universitat de Barcelona, Carrer Rosselló 153, E-08036, Barcelona, Catalonia, Spain.

²Centro de Investigação em Saúde de Manhiça (CISM), Rua 12, Cambeve, Vila de Manhiça, CP 1929 Maputo, Mozambique.

³Department of Physiologic Science, Clinical Pharmacology, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.

⁴Present address: London School of Hygiene and Tropical Medicine (LSHTM). Keppel Street, WC1E 7HT, London, UK.

⁵U.S. Military Malaria Vaccine Program, Walter Reed Army Institute of Research (WRAIR), Silver Spring, Maryland, USA.

⁶Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Melbourne, VIC, Australia.

⁷Université Sorbonne Paris Cité, Université Paris Diderot, Inserm, INTS, Unité Biologie Intégrée du Globule Rouge UMR_S1134, Laboratoire d'Excellence GR-Ex, Paris, France.

⁸Institute of Immunology & Infection Research and Centre for Immunity, Infection & Evolution, Ashworth Laboratories, School of Biological Sciences, University of Edinburgh, King's Buildings, Charlotte Auerbach Rd, Edinburgh, EH9 3FL, UK.

⁹Burnet Institute, Melbourne, VIC 3004, Australia.

+Contributed equally

#Contributed equally and share senior authorship.

*Correspondence: gemma.moncunill@isglobal.org; carlota.dobano@isglobal.org

Summary

Objectives

Maternal *Plasmodium falciparum*-specific antibodies may contribute to protect infants against severe malaria. Our main objective was to evaluate the impact of maternal HIV infection and placental malaria on the cord blood levels and efficiency of placental transfer of IgG and IgG subclasses.

Methods

In a cohort of 341 delivering HIV-negative and HIV-positive mothers from southern Mozambique, we measured total IgG and IgG subclasses in maternal and cord blood pairs by quantitative suspension array technology against eight *P. falciparum* antigens: Duffy-binding like domains 3-4 of VAR2CSA from the erythrocyte membrane protein 1, erythrocyte-binding antigen 140, exported protein 1 (EXP1), merozoite surface proteins 1, 2 and 5, and reticulocyte-binding-homologue-4.2 (Rh4.2). We performed univariable and multivariable regression models to assess the association of maternal HIV infection, placental malaria, maternal variables and pregnancy outcomes on cord antibody levels and antibody transplacental transfer.

Results

Maternal antibody levels were the main determinants of cord antibody levels. HIV infection and placental malaria reduced the transfer and cord levels of IgG and IgG1, and this was antigen-dependent. Low birth weight was associated with an increase of IgG2 in cord against EXP1 and Rh4.2.

Conclusions

We found lower maternally transferred antibodies in HIV-exposed infants and those born from mothers with placental malaria, which may underlie increased susceptibility to malaria in these children.

Keywords

Maternal antibodies; cord blood antibodies; placental transfer; HIV; placental malaria; IgG; IgG subclasses.

1 **Introduction**

2 Each year, more than 200 million cases of malaria occur worldwide, the majority in Africa [1].
3 Pregnant women and children older than 6 months of age are the most vulnerable groups
4 affected by malaria. In fact, malaria in pregnancy is estimated to account for 100,000 neonatal
5 deaths annually and it increases the risk of severe maternal anaemia, premature delivery, low
6 birth weight (LBW) and perinatal mortality [2, 3]. The lower impact of malaria disease in
7 infants younger than 6 months of age is thought to be due to a number of factors, such as
8 passive transfer of maternal antibodies or higher presence of foetal haemoglobin associated with
9 slower parasite growth [4–8]. However, recent reports show that the number of malaria cases
10 may be underestimated [9, 10] and the risk of severe malaria increases when the transferred
11 maternal antibodies start to wane [11].

12 Maternal antibodies contribute to protection of infants for the first 3-6 months of life by passive
13 immunity, especially from severe malaria and its major complications [12, 13]. This immunity
14 is acquired mainly through the transplacental transfer of antibodies that is facilitated by neonatal
15 fragment crystallisable (Fc) region receptor (FcRn), expressed in the human syncytiotrophoblast
16 [14]. Only IgG is transferred across the placenta, the majority during the third trimester [15].

17 The efficiency of transplacental transfer of antibodies is affected by many factors, such as
18 maternal antibody levels, IgG subclass, avidity, antigen specificity, gestational age, parity,
19 maternal infections, and differs between locations [16–20]. Maternal hypergammaglobulinemia,
20 LBW and maternal infections have been inconsistently associated with reduced cord blood
21 antibody levels and placental transfer [21–26]. Malaria in pregnancy, for example, has been
22 reported to reduce transplacental IgG transfer against several common pathogen antigens in
23 some studies [19, 21, 23, 27], although others have shown no impact [23, 25, 26, 28].

24 The effect of maternal HIV infection is also controversial. A study in Kenya showed that HIV-
25 positive (HIV+) women had less transplacental transfer of IgG against the circumsporozoite
26 protein (CSP) than HIV-negative (HIV-) women, but no differences were found for any other

malarial antigen [29]. Another study in Kenya assessed the effect of maternal HIV infection on the transplacental transfer of 14 *P. falciparum* antigen-specific IgG antibodies and reported that HIV+ women had a reduced transfer of IgG only against the merozoite surface protein 9 (MSP9), CSP and erythrocyte binding antigen 181 (EBA181) [28]. In contrast, a study in Mozambique found that HIV+ women had a subclass-dependent reduction of cord blood IgG and placental transfer, with lower total IgG and IgG1 cord blood levels and placental transfer against erythrocyte binding antigen 175 (EBA 175), lower total IgG against apical membrane antigen 1 (AMA1) and lower IgG3 levels and placental transfer against merozoite surface protein 1 (MSP1) [30]. That study also assessed the effect of malaria in pregnancy, which reduced the transfer of antibodies against these antigens, and others have also reported reduced placental transfer of antibodies due to placental malaria [19]. Another study in Cameroon showed that there was a decreased transfer of CSP, MSP1 and AMA1 IgG antibodies in HIV+ mothers [31]. Moreover, only a few studies assessed the effect of maternal HIV infection on IgG subclasses against malaria, and they had several limitations: a low number of HIV+ women, a lack of viral load data, a small number of antigens tested and an absence of IgG2 and IgG4 analyses [30, 31]. Thus, further studies are needed to clarify the impact of maternal HIV infection on the transplacental transfer of antimalarial antibodies, especially IgG subclasses that have been reported to have differential associations with protection from malaria in childhood [32–36].

Maternal antibodies to *P. falciparum* antigens, could also interfere with the acquisition of a protective immune response after malaria vaccination, as suggested in previous studies [37–39], especially when the transferred antibodies are against a vaccine target antigen. This is known to be a significant issue for measles vaccines [40–44]. Therefore, it is important to decipher the factors that affect maternal antimalarial antibody transfer, not only because of their protective role in the infant, but also because of their implications on the antibody build-up against some vaccine target antigens and naturally acquired immunity (NAI) to malaria [45, 46].

Here, our main objective was to evaluate the effect of maternal HIV infection and placental malaria (PM), on the cord blood levels and placental transfer of total IgG and IgG subclasses to 8 *P. falciparum* antigens associated with malaria exposure and protection in a large sample size cohort of Mozambican women. As exploratory objectives, we also aimed to assess the impact of maternal variables (age, gravidity, malaria treatment, antiretroviral therapy, CD4⁺ T cell counts, HIV viral load), pregnancy outcomes (maternal anaemia, prematurity, gestational age and LBW) and seasonality.

A better understanding of factors affecting cord levels and placental transfer is essential towards the design and implementation of malaria vaccines, particularly in malaria endemic areas with high HIV prevalence.

Materials and Methods

Study design and sample collection

A total of 197 HIV- and 144 HIV+ pregnant women were recruited between May 2011 and September 2012 in the Manhica District, Southern Mozambique, a semi-rural area in Maputo Province. These women were participants of two clinical trials of antimalarial intermittent preventive treatment in pregnancy (IPTp, ClinicalTrialGov NCT00811421) (Additional file 1: Figure S1) [47, 48] that evaluated i) mefloquine (MQ) as an alternative IPTp drug to sulfadoxine-pyrimethamine (SP) in HIV- pregnant women and ii) MQ as IPTp drug in HIV+ pregnant women in whom SP is contraindicated and who received daily cotrimoxazole (CTX). Pregnant women of all gravidities and gestational age ≤ 28 weeks attending an antenatal care clinic for the first time and who had not received IPTp during their current pregnancy were invited to participate in the study after provision of informed consent. The study arms for the first trial were (1) SP, (2) single dose MQ (MQ full), and (3) split dose over two days MQ (MQ split), and for the second trial, women received either three monthly doses of MQ or placebo. Antiretroviral therapy (ART) with daily monotherapy with zidovudine (AZT) was recommended when CD4⁺ T cell count was below <350 cells/ μ L and/or when women were in

WHO HIV clinical stage III or IV [49]. At the time of the study, the intensity of malaria transmission was low/moderate and the HIV prevalence in pregnant women was 29% [50, 51].

Before delivery, 50 µl of maternal peripheral blood samples were collected on Whatman 903TM filter paper at recruitment and in two visits (one during the second trimester and the other during the third trimester) for the detection of *P. falciparum* by real-time quantitative polymerase-chain-reaction (qPCR) targeting the 18S ribosomal RNA [52]. Data of qPCR were available for 287 women (at recruitment), 240 women (visit 1) and 74 women (visit 2).

At delivery, a total of 332 plasma samples from peripheral blood (195 HIV- and 137 HIV+) and 303 cord blood samples (178 HIV- and 125 HIV+) were available. Peripheral blood smears were performed according to standard procedures for the microscopic detection of *P. falciparum* species [47, 48] and data were available for 308 women (183 HIV- and 125 HIV+). 50 µl of maternal peripheral blood were also collected at delivery on Whatman 903TM filter paper for the detection of *P. falciparum* by qPCR, and data were available for 242 women (163 HIV- and 79 HIV+).

To assess PM, placental blood was collected to perform blood smears and qPCR. Data of blood smears and qPCR were available for 340 (197 HIV- and 143 HIV+) and 236 (157 HIV- and 79 HIV+) women, respectively. Tissue samples from the maternal side of the placenta were also collected and placental histology was performed on samples from 307 study participants. Acute PM was defined by the presence of parasites on sections without malaria pigment; chronic PM, by presence of parasites and pigment; or past PM, by the presence of pigment alone. PM was considered positive if any of the tests performed (blood smear, qPCR or histology) were positive, therefore the 341 women had PM data for at least one of the tests.

Antibody assays

For the quantification of IgG, IgG1, IgG2, IgG3 and IgG4 responses, quantitative suspension array technology (qSAT) applying the xMAPTM technology (Luminex Corp., TX) was performed.

Eight *P. falciparum* recombinant proteins were selected for our analysis: Duffy-binding like domains 3-4 (PfEMP1 DBL3-4 of var2csa PfEMP1, INSERM) [53], erythrocyte-binding antigen 140 (EBA140, Burnet Institute) [54], exported protein 1 (EXP1, Sanaria) [55], 42 kDa fragment of merozoite surface protein 1 (MSP1₄₂, WRAIR) [56], merozoite surface protein 1 block 2 (MSP1 bl2, University of Edinburgh) [57], merozoite surface protein 2 (MSP2, University of Edinburgh) [58], merozoite surface protein 5 (MSP5, Monash University) [59] and reticulocyte-binding-homologue-4.2 (Rh4.2, Burnet Institute) [60]. The proteins included in the panel are a selection of *P. falciparum* pregnancy-specific markers (DBL3-4) [53] and markers of malaria exposure (EXP1, MSP1₄₂ and MSP2) and immunity (EBA140, MSP1 bl2, MSP5 and Rh4.2) as defined in our previous study [38].

Standardization and optimization of the qSAT assays were previously performed to control for sources of variability [61–63]. First, antigens covalently coupled to MagPlex beads and resuspended in 50µL of PBS, 1% BSA, 0.05% Azide pH 7.4 (PBS-BN) were added to a 96-well µClear® flat bottom plate (Greiner Bio-One) in multiplex. Fifty µL of test samples, negative or positive controls [64] were added to multiplex wells and incubated overnight at 4°C protected from light. After incubation, plates were washed three times with PBS-Tween 20 0.05%. Then, 100µL of anti-human IgG (Sigma B1140, dilution 1/2500), anti-human IgG1 (Abcam ab99775, dilution 1/4000), anti-human IgG2 (Invitrogen MA1-34755, dilution 1/500), anti-human IgG3 (Sigma B3523, dilution 1/1000) or anti-human IgG4 (Invitrogen MA5-16716, dilution 1/500) were added and incubated for 45 min. After another plate washing cycle, 100µL of streptavidin-R-phycoerythrin (Sigma 42250) at 1/1000 dilution was added and incubated 30 min for IgG, IgG1 and IgG3. For IgG2 and IgG4, 100 µL of anti-mouse IgG (Fc-specific)–biotin (Merck B7401, 1/40000 and 1/10000 dilution, respectively) was added and incubated for 45 min, followed by another washing cycle and then incubation with streptavidin-R-phycoerythrin for 30 min. Finally, plates were washed and beads were resuspended in 100 µL/well of PBS-BN. The Luminex 100/200 analyser was used for reading the plates and at least 20 microspheres per

analyte were acquired per sample. Antibody levels were measured as median fluorescence intensity (MFI). Data were captured using xPonent software.

Test samples were assayed at 2 dilutions for IgG (1/250 and 1/10000), and IgG1 and IgG3 (1/100 and 1/2500). Only 1 dilution was tested for IgG2 and IgG4 (1/50) because of their usual low levels. A positive control (WHO Reference Reagent for anti-malaria *P. falciparum* human serum, NIBSC code: 10/198) in twelve serial dilutions (1:3, starting at 1/25) was used for QA/QC and to select optimal sample dilution for data analysis. For quality control, two blanks were added to each plate. Test samples were distributed across plates ensuring balanced groups.

Statistical analysis

MFI data were $\log_{10}$ -transformed. The Shapiro-Wilk test of normality and the quantile-quantile (Q-Q) plot were performed to evaluate the distribution of such $\log_{10}$ -transformed MFI antibody data. Boxplots and radar charts were used to represent the differences on antibody levels ($\log_{10}$ MFI) and placental transfer (measured as the cord blood/mother ratio) between groups of categorical variables (HIV and PM). The non-parametric Mann-Whitney U test was used to compare antibody levels and placental transfer between groups as $\log_{10}$ MFI data were not normally distributed. Due to the high dimensionality of the data regarding the number of variables (5 IgG and IgG subclasses and 8 antigen combinations), Principal Component Analysis (PCA) of the cord and maternal blood $\log_{10}$ MFI data was performed to explore and visualize overall antibody patterns. Only individuals with complete data for all the antigens and antibodies were included in the PCA analysis. The aim of a PCA analysis is to find a new reduced set of variables (called principal components, or dimensions) that explain as much of the information in the dataset as possible. The first dimension contains the most information about the original dataset, and explains most of the variation, and the last contains the least. We selected the two principal components or dimensions that best explained the variance of the data and plotted the PCA scores. These plots allow visualizing clusters of samples based on their similarity.

Univariable linear regression models were performed to determine the effect of covariables on the cord blood antibody levels or placental transfer of antibodies. The variables analysed in the univariable models were maternal antibody levels ($\log_{10}$ MFI), maternal HIV infection, PM, age, gravidity (defined as primigravidae and multigravidae), maternal anaemia (defined as haemoglobin levels $<11\text{g/dL}$), LBW (defined as $<2500\text{g}$ at birth), prematurity (defined as delivery before 37 weeks of gestational age), gestational age (measured by Ballard score [65]), treatment arms (defined as MQ or placebo in the HIV+ women study and MQ full, MQ split or SP in HIV- women study), antiretroviral therapy (ART) received before pregnancy, started at recruitment or not received at all, CD4^+ T cell counts ($<350\text{ cells}/\mu\text{L}$ or $\geq 350\text{ cells}/\mu\text{L}$), HIV viral load (<400 , 400-999, 1000-9999 and $>9999\text{ copies/mL}$), and seasonality (dry or rainy). Gravidity was defined as primigravidae and multigravidae following the approach used in previous studies and due to the lack of significant differences on antibody levels between secundigravidae and multigravidae in other studies [47, 48, 66–68]. Seasonality was defined as rainy if at least 4 of the pregnancy months fell under the category of rainy period (November–April), and defined as dry in any other case. Multivariable regression analyses were performed for each antigen and IgG or IgG subclass including always maternal antibody levels and maternal HIV infection (statistically significantly associated in all univariable analyses) and the additional predictors that resulted in the best fitted and simpler (less variables) models. Specifically, we tested exhaustively all possible combinations of the predictor variables and selected the models with lower Akaike information criterion (AIC) and Bayesian information criterion (BIC) and higher adjusted r-square. Then, variables that appeared significant in most of the best models for each antigen/subclass and that also had more significant associations in univariable analyses (significant adjusted p-values) were included in all the models, i.e. PM and LBW. The betas obtained in each case were transformed into a percentage for interpretation. For maternal antibody levels (log-log model) the beta transformed value (%) was calculated with the formula $((10^{(\beta \cdot \log_{10}(1.1))} - 1) \cdot 100)$. This represents the effect (in percentage) of a 10% increase in the corresponding predictor variable on IgG and IgG subclass cord blood levels. For maternal HIV infection, PM and LBW (log-linear models), the beta transformed value (%) was

calculated with the formula $((10^{\beta})-1)*100$. This gives the difference (in percentage) in IgG and IgG subclass cord blood levels or placental transfer between the reference group and the study group (e.g. the difference between cord antibody levels of HIV- women compared with HIV+ women cord antibody levels).

All p-values were considered statistically significant when <0.05 after adjusting for multiple testing through Benjamini-Hochberg. Adjustments for multiple testing were done separately for each IgG subclass. Data were managed and analysed using the R software version 3.6.3 and its package devtools [69]. The ggplot2 package was used to perform boxplot graphs [70]. The FactoMineR [71] and factoextra [72] packages were used to perform PCA.

Results

Description of participants

Study participants consisted of 341 pregnant women (197 HIV- and 144 HIV+) (Table 1). Their median age was 25 years old (interquartile range [IQR] 19-29) and HIV+ women (median of 27 years) were older than HIV- women (median of 21 years). Less than a fourth (24%) of the participants were primigravidae, and there were more primigravidae in the HIV- group (35%) compared to the HIV+ group (9%). Maternal anaemia was more prevalent among HIV+ women (68.8%) than HIV- women (56.2%). No significant differences were found in birth weight or prematurity between infants born to HIV+ and those born to HIV- women. Only 20 women had PM and the proportion of PM between HIV+ and HIV- women was similar: 13 HIV- (6.6%) and 7 HIV+ (4.9%). Among these 20 women, 3 had acute PM and 8 past PM (defined through histology), 5 had positive placental blood smears and 11 had positive placental qPCR, of which 7 were only qPCR positive. A total of 51 women had peripheral malaria (positive in peripheral blood by microscopy and/or PCR at any of the visits during pregnancy) but there were no differences by HIV infection.

Profile of cord blood antibody levels and placental transfer to *P. falciparum* antigens

The PCA analysis of antibody levels in 303 cord and 332 maternal blood samples showed very similar patterns (maternal antibody PCA analyses not shown). Clusters showing similarity of responses were detected in cord antibody levels by IgG subclasses (Fig. 1a) and antigens (Fig. 1b). While dimension 1 explained the majority of the variance and contributed to the separation of IgG4, IgG2 and IgG/IgG1/IgG3, dimension 2 contributed to the separation of the IgG1 and IgG3 responses (Fig. 1a) and MSP1 bl2, MSP2 from the rest of the antigens (Fig. 1b). DBL3-4 greatly contributed to IgG1 whereas MSP1 bl2 and MSP2 contributed more to the IgG3 responses (Fig. 1a). DBL3-4 was clearly separated from the rest indicating a different antibody profile (Fig. 1b). Consistently, DBL3-4 had lower IgG3 levels and MSP1 bl2 and MSP2 had lower IgG1 levels than the other antigens (Fig. 1c). Overall, IgG2 had lower median levels than IgG1 and IgG3 for most antigens, except for MSP1 bl2, MSP2 and DBL3-4. The lowest levels were shown for IgG4 in all antigens, with especially very low responses for DBL3-4, MSP5 and Rh4.2 (Fig. 1c).

For the placental transfer, DBL3-4 antibodies were the most efficiently transferred, especially IgG4 followed by IgG3 and finally IgG2 (Fig. 1d). For the rest of antigens, the four IgG subclasses showed similar placental transfer, of which IgG2 was the lowest.

Altered maternal and cord blood anti-*P. falciparum* IgG levels by HIV and placental malaria

First, we compared total IgG levels in HIV+ and HIV- mothers for 332 maternal (137 HIV+ and 195 HIV-), and 303 cord samples (125 HIV+ and 178 HIV-). In HIV+ women, both maternal and cord blood IgG levels were lower for EXP1 and MSP5 (Fig. 2a). Second, we assessed the differences between mothers with and without PM in maternal and cord total IgG levels (Fig. 2b). IgG levels against MSP2 were higher among women with PM than those without PM. Also, cord blood IgG levels against EXP1 and MSP2 were higher among women with PM.

We also looked at the differences in maternal and cord IgG subclasses levels by HIV infection (Fig. 2c). In HIV+ women, maternal levels were lower for IgG1 DBL3-4, MSP2 and MSP5 than for HIV- women (Fig. 2c). Maternal levels of IgG2 against EXP1 and MSP2 were also lower in

HIV+ women compared with HIV- women. IgG3 maternal levels were only lower among HIV+ women against DBL3-4, whereas IgG4 levels in HIV+ women were lower than HIV- women against EBA140, EXP1, MSP1₄₂ and MSP1 bl2. Statistically significant differences were found in the cord for the same antigens and IgG subclasses as in the mother, with the exception of DBL3-4 IgG3 and EXP1 IgG4 that were not significantly different in the cord. Regarding PM, there were no significant differences between women with and without PM in IgG subclass levels, although there was a general positive trend in women with PM (Additional file 1: Figure S2-S3).

Factors associated with anti-*P. falciparum* IgG cord blood levels

For the multivariable analyses, we selected log₁₀ MFI maternal antibodies, HIV infection, PM and LBW, as they were significant in univariable models (Supplementary material 1) and improved the model performances, having lower AIC and BIC, and higher adjusted r-squares. Maternal antibody levels had a high positive correlation with cord blood antibody levels for all the antigens and subclasses (Fig. 3a). A 10% increase in maternal total IgG levels and IgG subclasses was associated with 6.03% to 9.75% increases in total IgG and IgG subclass cord blood levels, depending on the antigen and IgG subclass.

Maternal HIV infection was negatively associated with cord blood antibody levels, reducing IgG to EXP1 and MSP5 by 3.84% and 1.47%, respectively; IgG1 to MSP2 and Rh4.2 by 9.09% and 3.12%, respectively; and IgG4 to MSP1₄₂ by 1.91%. No significant effect was found for IgG2 and IgG3 levels in cord blood (Fig. 3b). PM negatively impacted IgG cord blood levels against EBA140, MSP1 bl2 and Rh4.2 (2.19%, 2.53% and 3.52% reduction, respectively), and IgG2 to EBA140 (4.58% reduction) (Fig. 3c). When analysing HIV+ women only, PM was also associated with lower IgG2 to DBL3-4 (Additional file 1: Figure S4). LBW was positively associated with cord blood IgG2 levels against EBA140 and Rh4.2, with a 5.46% and 8.14%, increase, respectively (Fig. 3d). No significant associations were found for LBW and total IgG or the rest of the subclasses. Age, maternal anaemia, gravidity, IPTp treatment, prematurity,

seasonality, and CD4⁺ T cell counts, ART and viral load for HIV⁺ women were not included in the models following the AIC, BIC and r-square criteria.

Decreased placental transfer of anti-*P. falciparum* IgGs by HIV and placental malaria

The radar charts (Fig. 4) showed that HIV⁺ women had a reduced placental transfer of antibodies compared to HIV⁻ women. This was significant for IgG and IgG1 against DBL3-4, EBA140, EXP1, MSP1₄₂, MSP1 bl2, MSP2 and MSP, IgG1 against Rh4.2 (Fig. 4a-4b), and IgG4 against MSP1₄₂ (Additional file 1: Figure S4). However, HIV infection increased the transfer of IgG4 against DBL3-4 and also a trend was seen for IgG3 (Additional file 1: Figure S5). No significant differences in placental transfer between the two groups were found for IgG2 or IgG3.

In multivariable models including HIV, PM and LBW (variables showing an effect on placental antibody transfer in univariable models (Supplementary Material 1) and that when included in the models these had lower AIC and BIC and higher adjusted r-square), HIV infection was associated with a reduced placental transfer of IgG against EXP1 (3.10% reduction) and IgG1 against MSP2 and Rh4.2 (8.01% and 2.84% reductions, respectively) (Fig. 5a). PM was associated with a diminished placental transfer of IgG to MSP1 bl2 and Rh4.2 (3.47% and 4.46% reductions, respectively) (Fig. 5b). LBW did not have any significant impact on transplacental transfer of antibodies, although when considering raw p-values LBW was associated with higher placental transfer of IgG2 to EXP1, MSP5 and Rh4.2 (Fig. 5c). No additional variables were included in the multivariable analysis as they did not provide any added value to the models following the AIC, BIC and r-square criteria.

Discussion

Our study provides a better understanding of the factors that affect placental transfer and cord blood levels of anti-malarial antibodies, especially IgG subclasses, which are relevant for malaria protection during the first months of life. We found that the main determinant of cord

antibody levels was the corresponding maternal levels, and that maternal HIV infection was generally associated with diminished cord IgG levels, although this effect was antigen-subclass dependent. Also, PM showed some association with lower cord blood IgG levels and placental transfer against malaria immunity-related antigens.

The highly associated mother and cord blood antibody levels are consistent with previous studies [19, 30, 73, 74]. The maternal antibodies transferred to the newborn are suggested to be protective against malaria infection during the first months of life. At the same time, these transferred antibodies may interfere with the acquisition of protective antibodies after malaria vaccination, as seen in RTS,S/AS01E immunisation against CSP and indirectly against non-CSP protection-related antigens [37–39].

Reaching protective cord antibody levels against malaria is essential for the newborn but HIV infection and PM could interfere with the efficiency of this passive immunity. Here, maternal HIV infection was associated with diminished antibody levels in the cord, but this was strongly antigen-subclass dependent, in line with previous studies in which maternal and cord IgG levels against some antigens related to malaria exposure and protection were lower in HIV+ women [28, 30, 31]. These previous studies show some discrepancies with the effect of maternal HIV infection on antimalarial cord antibody levels and placental transfer, and this could be due to different malaria prevalence, study sample sizes, sensitivities among the serological methods, and the variables used in the model adjustment [28, 30, 31].

Despite the low number of women with any evidence of PM in the study, PM also had an impact on the anti-malarial IgG transplacental transfer. Reduced transplacental transfer of antibodies associated with PM has been found in several studies [19, 26, 75] and may be due to damaged placental tissue. *P. falciparum*-infected erythrocytes and immune cells infiltrate within the intervillous spaces of the placenta causing inflammation, fibrinoid necrosis, basal membrane thickening and increase of the number of syncytial knots, and it may alter the exchange system between mother and foetus, including Fc receptors [76, 77].

Due to the importance of IgG subclasses on antimalarial effector immunity we wanted to assess their levels in the mother and their transfer to the foetus. Cord IgG1 and IgG3 levels were the highest and IgG4 the lowest for most antigens. In contrast, for most of the antigens, IgG4 was the most efficiently transferred, especially for the pregnancy-specific *P. falciparum* antigen DBL3-4 VAR2CSA, followed by IgG1 or IgG3 (depending on the antigen) and finally IgG2. This could be explained by lower maternal antibody concentrations having higher active placental transport [78]. Indeed, DBL3-4 had the highest placental transfer efficacy of IgG4 despite cord IgG4 levels being the lowest. This ranking was unexpected because IgG1 followed by IgG4, IgG3 and finally IgG2 have been commonly stated as the best transferred subclasses [15, 79], although a recent manuscript reported a hierarchy of IgG1>IgG3>IgG4=IgG2 and identified a number of other studies that also observed different transfer efficiencies [80], such as our recent report [74]. This suggests that the IgG subclasses transfer efficiency may vary between study populations, as well as by maternal antigen exposure.

IgG1 and IgG3 are cytophilic antibodies, which can interact with complement and Fc γ -receptors [81], and are considered to be protective [32, 33, 82]. Therefore, their high cord levels could be related with an effective induction of effector functions that are essential for *Plasmodium* clearance, as previously seen with members of the PfRh [83, 84], EBA invasion ligand families [35] and MSP5 [85]. IgG2 and IgG4 are non-cytophilic antibodies and have been classically correlated with disease [32, 86]. However, we recently proposed that the pattern of cytophilic and non-cytophilic IgG antibodies is antigen-dependent and both types could be involved in protection [34] since not all protective mechanisms require Fc-mediation [87]. A shift from anti-MSP2 IgG1 in primary malaria infections towards IgG3 in subsequent malaria infections indicates that IgG3 could be related with protection [88, 89], similarly to MSP1 bl2 IgG3 [90]. Anti-IgG2 MSP2 increases with age and inversely associates with risk of infection, while IgG4 levels have been positively associated with risk [91]. Thus, the high anti-MSP2 IgG2 and IgG3 levels in the cord and lower IgG4 we observe could be associated with malaria protection in

infants. However, the relative importance of IgG subclasses in protective immunity is not clear and further research is needed in this regard.

HIV infection reduced IgG1 cord levels against MSP2 and Rh4.2 due to an impairment of the IgG1 transplacental transfer. Although it has been previously reported that maternal HIV negatively affected MSP1 IgG1 [30, 31] and IgG3 [30] cord levels, we did not find any significant association between HIV infection and MSP1 IgG1-3 cord levels. However, we observed lower IgG4 cord levels against MSP1₄₂. Diminished levels of these antibodies could explain higher risk of infection, as cytophilic antibodies have been suggested to contribute to protection from clinical malaria in adults and children in endemic areas [34, 92] and IgG4 subclass has also been associated with malaria protection [34, 93]. LBW was previously associated with a reduction in cord blood levels and placental transfer of antibodies [94–96], but in this study we did not observe any association of LBW with lower cord levels or placental transfer. However, our results are consistent with other studies that did not show any impact of LBW on IgG and subclass cord levels against some antimalarial antigens [30, 31]. Surprisingly, LBW was associated with higher cord IgG2 levels against EXP1 and Rh4.2 and, to our knowledge, this is the first time that this observation has been reported. IgG2 antibodies are associated with increased risk of severe malaria [97] and, therefore, LBW infants may have higher risk to suffer from malaria complications than normal weight infants. No associations were found between maternal age, anaemia, gravidity and IPTp treatment and cord levels or placental transfer of antibodies against antimalarial antigens [28, 30]. We did not find either any significant differences between mothers who initiated ART before pregnancy, mothers who started during pregnancy, and mothers not taking ART. Previous studies on the effect of ART on placental transfer of antibodies are controversial and the effect varied depending upon the antigen, the initiation and type of treatment, and the dose. For example, Goetghebuer et al. observed the lowest maternal antibody transfer ratios against 5 vaccine and 2 pathogen antigens in HIV+ mothers who initiated ART during pregnancy, compared with those who initiated ART before pregnancy [98]. However, this study did not include *P. falciparum* antigens. Moro et al.

found reduced placental transfer of antibodies against MSP1, AMA1 and EBA175 in HIV+ women receiving no ART, although in this cohort women with ART were not included [30]. Ray et al. showed lower placental transfer of antibodies against the same antigens in women taking optimal ART treatment [28], suggesting that ART treatment did not make any difference in the transplacental transfer of these antimalarial antibodies. In the same line, Babakhanyan et al. reported lower placental transfer of antibodies against CSP, AMA1 and MSP1 in HIV+ women taking only nevirapine at delivery than HIV- women [31]. On the contrary, Ayisi et al. found that HIV+ women not receiving ART had reduced transfer of antibodies against CSP but not against MSP1 or EBA175 [29].

Our study is subjected to some limitations. Specifically, hypergammaglobulinemia, which has been associated with a reduced transplacental transfer of antibodies [23, 25, 26], was not measured. Chronic infections such as HIV, but also malaria, induce hypergammaglobulinemia [99, 100], and it has been reported that 94% of women with hypergammaglobulinemia also had PM [25]. Consequently, the effect of maternal HIV and PM on cord blood levels and placental transfer might be in part due to hypergammaglobulinemia. Another limitation is that we had a low number of PM cases, which may result in low statistical power to detect significant associations. In addition, qPCR data were not available from all women and, consequently, we may have missed some cases of submicroscopic PM (only detected by qPCR). This is of specially importance as there are studies reporting that women with submicroscopic PM had higher inflammation markers than women without PM [101, 102], which could affect the placental transfer of antibodies. Finally, the impact of the observed differences in cord antibody levels on the malaria risk in the infants was not evaluated of this cohort and will be addressed on future studies.

In conclusion, our results demonstrate that maternal HIV infection was associated with reduced levels of antibodies, mostly IgG and IgG1, against some antimalarial antigens in cord blood. Part of this reduction in antibody levels was due to altered antibody levels in the mother, which is the main determinant of cord blood levels, but HIV-infection also diminished transplacental

transfer of antibodies. PM also reduced IgG cord levels to some malaria protection-related antigens, and LBW was associated with increased anti-malaria IgG2 cord levels, also related to a higher risk of severe malaria in the infant. Overall, the findings are important for better understanding the role of maternal HIV infection and malaria in the placental transfer of antimalarial antibodies, which is essential for protecting the infant against the severe consequences of malaria during the first months of life.

Additional files

Additional file 1: Supplementary information including figures and methods. Figure S1. IPTp trial profile. Figure S2. Maternal blood antibody levels in women with PM and women without PM. Figure S3. Cord blood antibody levels in women with PM and women without PM. Figure S4. Effect of placental malaria on cord blood antibody levels in HIV+ women. Figure S5. Cord/mother ratios in HIV+ and HIV- women.

Supplementary material 1: Cord blood levels and placental transfer of antibodies univariable models.

Acknowledgments

We are grateful to the volunteers and their families; the clinical, field, and lab teams at the Manhica Health Research Centre, particularly the lab personnel Bendita Zavale, Lázaro Quimice, Elias Matusse, Eugenio Mussa and Edmundo José. Special thanks to Laura Puyol from ISGlobal for her logistic support and Robert Andrew Mitchell for proofreading and reviewing the manuscript. Thanks to Linda Reiling and Christine Langer (Burnet Institute) for expression of recombinant proteins.

Authors' contributions. SA, CD and GM wrote the first draft of the manuscript. SA, CD and GM conceived the immunological study and the experimental design and interpreted the data. CD, GM, RA and SA designed the analysis and selection of the antigens. SA and MV performed the antibody Luminex assay. EA, RLC, BG, DC and JGB contributed with the resources. GRO and MVS performed the statistical analysis. AM, CD and GM designed the immunology study ancillary to the clinical trials. MNM, RB and CJ processed the samples. PC and LFS performed the PCR. RG, MR, JJA, EM, AV, ES and CM designed and enrolled participants in the clinical trials. AN was the clinical trial data manager. JJA was the clinical trial statistician. RA, JB, PC, RG, CM, GRO and MVS contributed to the write up of the manuscript. All reviewed and approved the manuscript.

Funding. This study was supported by the European and Developing Countries Clinical Trials Partnership (EDCTP; IP.2007.31080.002); the Malaria in Pregnancy Consortium, which is funded by a grant from the Bill and Melinda Gates Foundation to the Liverpool School of Tropical Medicine; and the Instituto de Salud Carlos III (PI08/0564). The Centro de Investigação em Saude da Manhica receives core support from the Spanish Agency for International Cooperation and Development (AECID). The study received funds from MINECO (SAF2008-00743, RYC-2008-02631 to C.D.), from Instituto de Salud Carlos III (PS09/01113, PI13/01478 to A. Mayor) and the Department d'Universitats i Recerca de la Generalitat de Catalunya (AGAUR; 2017SGR664 to A.M., 2014SGR991 to C.D.). GM had the support of the Department of Health, Catalan Government (SLT006/17/00109). This research is part of the ISGlobal Program on the Molecular Mechanisms of Malaria which is partially supported by the Fundación Ramón Areces and we acknowledge support from the Spanish Ministry of Science and Innovation through the "Centro de Excelencia Severo Ochoa 2019-2023" Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. JGB is supported by the National Health and Medical Research Council of Australia (Investigator Grant 1173046).

Availability of data and materials

All data analysed during this study are included in this article and its supplementary information files or are available from the authors upon request.

Ethics approval and consent to participate

This study was carried out in accordance with ICH Good Clinical Practice guidelines and the Declaration of Helsinki. The study protocols and informed consent forms were reviewed and approved by the Comité Ètic d'Investigació Clínica (CEIC, Hospital Clínic, UB), Spain, and the Comité Nacional de Bioética (CNBS), Mozambique. Written informed consent was obtained from all participants.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Contributor Information

Selena Alonso, Email: selena.alonso@isglobal.org

Marta Vidal, Email: marta.vidal@isglobal.org

Gemma Ruiz-Olalla, Email: gemma.ruizolalla@isglobal.org

Raquel González, Email: raquel.gonzalez@isglobal.org

- 468 Chenjerai Jairoce, Email: chenjerai.jairoce@isglobal.org
- 469 M. Nelia Manaca, Email: marianelia.manaca@gmail.com
- 470 Miquel Vázquez-Santiago, Email: miquel.vazquez@isglobal.org
- 471 Reyes Balcells, Email: reyesbalcells@gmail.com
- 472 Anifa Vala, Email: anifa.vala@manhica.net
- 473 María Ruperez, Email: maria.ruperez@lshtm.ac.uk
- 474 Pau Cisteró, Email: pau.cistero@isglobal.org
- 475 Laura de la Fuente, Email: laura.delafuente@isglobal.org
- 476 Evelina Angov, Email: evelina.angov.civ@mail.mil
- 477 Ross L. Coppel, Email: ross.coppel@monash.edu
- 478 Benoit Gamain, Email: benoit.gamain@inserm.fr
- 479 David Cavanagh, Email: David.cavanagh@ed.ac.uk
- 480 James G. Beeson, Email: beeson@burnet.edu.au
- 481 Arsenio Nhacolo, Email: Arsenio.nhacolo@manhica.net
- 482 Esperança Sevene, Email: esperanca.sevene@manhica.net
- 483 John J. Aponte, Email: john.aponte@isglobal.org
- 484 Eusébio Macete, Email: eusebio.macete@manhica.net
- 485 Ruth Aguilar, Email: ruth.aguilar@isglobal.org
- 486 Alfredo Mayor, Email: alfredo.mayor@isglobal.org
- 487 Clara Menéndez, Email: clara.menendez@isglobal.org
- 488 Carlota Dobaño, Email: carlota.dobano@isglobal.org

Gemma Moncunill, Email: gemma.moncunill@isglobal.org

References

- [1] World Health Organization. *World Malaria Report 2020*. 2020. Epub ahead of print 2020. DOI: ISBN 978-92-4-001579-1.
- [2] Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. *Lancet Infectious Diseases* 2007; 7: 93–104.
- [3] Eisele TP, Larsen DA, Walker N, et al. Estimates of child deaths prevented from malaria prevention scale-up in Africa 2001–2010. *Malar J*; 11. Epub ahead of print 2012. DOI: 10.1186/1475-2875-11-93.
- [4] Dicko-Traoré F, Sylla M, Djimdé AA, et al. Congenital and neonatal malaria in sub-sahara Africa, a scarce event? *J Pediatr Pueric*. Epub ahead of print 2011. DOI: 10.1016/j.jpp.2011.01.002.
- [5] Afolabi BM, Salako LA, Mafe AG, et al. Malaria in the first 6 months of life in urban African infants with anemia. *Am J Trop Med Hyg* 2001; 65: 822–827.
- [6] Klouwenberg PMCK, Oyakhirome S, Schwarz NG, et al. Malaria and asymptomatic parasitaemia in Gabonese infants under the age of 3 months. *Acta Trop* 2005; 95: 81–85.
- [7] Laru B, Molyneux E, Ter Kuile FO, et al. Malaria in infants below six months of age: Retrospective surveillance of hospital admission records in Blantyre, Malawi. *Malar J*; 8. Epub ahead of print 2009. DOI: 10.1186/1475-2875-8-310.
- [8] Billig EM, McQueen PG, McKenzie FE. Foetal haemoglobin and the dynamics of paediatric malaria. *Malar J* 2012; 11: 396.
- [9] D'Alessandro U, Ubben D, Hamed K, et al. Malaria in infants aged less than six months - Is it an area of unmet medical need? *Malaria Journal* 2012; 11: 400.
- [10] Ceesay SJ, Koivogui L, Nahum A, et al. Malaria prevalence among young infants in different transmission settings, Africa. *Emerg Infect Dis* 2015; 21: 1114–1121.
- [11] Schumacher RF, Spinelli E. Malaria in children. *Mediterranean Journal of Hematology and Infectious Diseases*; 4. Epub ahead of print 2012. DOI: 10.4084/MJHID.2012.073.
- [12] Riley EM, Wagner GE, Akanmori BD, et al. Do maternally acquired antibodies protect infants from malaria infection? *Parasite Immunology* 2001; 23: 51–59.
- [13] Kurtis JD, Raj DK, Michelow IC, et al. Maternally-derived Antibodies to Schizont Egress Antigen-1 and Protection of Infants from Severe Malaria. *Clin Infect Dis* 2019; 68: 1718–1724.
- [14] Simister NE, Story CM, Chen H-LL, et al. An IgG-transporting Fc receptor expressed in the syncytiotrophoblast of human placenta. *Eur J Immunol* 1996; 26: 1527–1531.
- [15] Malek A, Sager R, Kuhn P, et al. Evolution of Maternofetal Transport of Immunoglobulins During Human Pregnancy. *Am J Reprod Immunol* 1996; 36: 248–255.
- [16] Avanzini M, Pignatti P, Chirico G, et al. Placental transfer favours high avidity IgG antibodies. *Acta Paediatr* 2007; 87: 180–185.
- [17] Caceres VM, Strebel PM, Sutter RW. Factors Determining Prevalence of Maternal Antibody to Measles Virus throughout Infancy: A Review. *Clin Infect Dis* 2000; 31: 110–119.

- 531 [18] Scott S, Cumberland P, Shulman CE, et al. Neonatal Measles Immunity in Rural Kenya:
532 The Influence of HIV and Placental Malaria Infections on Placental Transfer of
533 Antibodies and Levels of Antibody in Maternal and Cord Serum Samples. *J Infect Dis*
534 2005; 191: 1854–1860.
- 535 [19] McLean ARD, Stanicic D, McGready R, et al. P. falciparum infection and maternofetal
536 antibody transfer in malaria-endemic settings of varying transmission. *PLoS One*; 12.
537 Epub ahead of print 1 October 2017. DOI: 10.1371/journal.pone.0186577.
- 538 [20] Charnaud SC, McGready R, Hertzen-Crabb A, et al. Maternal-foetal transfer of
539 Plasmodium falciparum and Plasmodium vivax antibodies in a low transmission setting.
540 *Sci Rep*; 6. Epub ahead of print 10 February 2016. DOI: 10.1038/srep20859.
- 541 [21] Cumberland P, Shulman CE, Maple PA, et al. Maternal HIV infection and placental
542 malaria reduce transplacental antibody transfer and tetanus antibody levels in newborns
543 in Kenya. *J Infect Dis* 2007; 196: 550–557.
- 544 [22] Jones CE, Kampmann B, Hesselning A. Maternal HIV infection and antibody responses
545 in uninfected infants: In reply. *JAMA - Journal of the American Medical Association*
546 2011; 305: 1964–1965.
- 547 [23] Okoko BJ, Wesuperuma LH, Ota MO, et al. Influence of placental malaria infection and
548 maternal hypergammaglobulinaemia on materno-foetal transfer of measles and tetanus
549 antibodies in a rural west African population. *J Health Popul Nutr* 2001; 19: 59–65.
- 550 [24] Okoko BJ, Wesumperuma LH, Hart AC. Materno-foetal transfer of H. influenzae and
551 pneumococcal antibodies is influenced by prematurity and low birth weight: implications
552 for conjugate vaccine trials. *Vaccine* 2001; 20: 647–50.
- 553 [25] Atwell JE, Thumar B, Robinson LJ, et al. Impact of placental malaria and
554 hypergammaglobulinemia on transplacental transfer of respiratory syncytial virus
555 antibody in Papua New Guinea. *J Infect Dis* 2016; 213: 423–431.
- 556 [26] Okoko BJ, Wesumperuma LH, Ota MO, et al. The influence of placental malaria
557 infection and maternal hypergammaglobulinemia on transplacental transfer of antibodies
558 and IgG subclasses in a rural West African population. *J Infect Dis* 2001; 184: 627–632.
- 559 [27] Brair M-E, Brabin B, Milligan P, et al. Reduced transfer of tetanus antibodies with
560 placental malaria. *Lancet* 1994; 343: 208–209.
- 561 [28] Ray JE, Dobbs KR, Ogolla SO, et al. Reduced Transplacental Transfer of Antimalarial
562 Antibodies in Kenyan HIV-Exposed Uninfected Infants. *Open Forum Infect Dis*; 6. Epub
563 ahead of print 1 June 2019. DOI: 10.1093/ofid/ofz237.
- 564 [29] Ayisi JG, Branch OLH, Rafi-Janajreh A, et al. Does infection with human
565 immunodeficiency virus affect the antibody responses to Plasmodium falciparum
566 antigenic determinants in asymptomatic pregnant women? *J Infect* 2003; 46: 164–172.
- 567 [30] Moro L, Bardaji A, Nhampossa T, et al. Malaria and HIV Infection in Mozambican
568 Pregnant Women Are Associated With Reduced Transfer of Antimalarial Antibodies to
569 Their Newborns. *J Infect Dis* 2015; 211: 1004–1014.
- 570 [31] Babakhanyan A, Ekali GL, Dent A, et al. Maternal human immunodeficiency virus-
571 associated hypergammaglobulinemia reduces transplacental transfer of immunoglobulin
572 G to Plasmodium falciparum antigens in Cameroonian neonates. *Open Forum Infect Dis*.
573 Epub ahead of print 2016. DOI: 10.1093/ofid/ofw092.
- 574 [32] Bouharoun-Tayoun H, Druilhe P. Plasmodium falciparum malaria: Evidence for an
575 isotype imbalance which may be responsible for delayed acquisition of protective
576 immunity. *Infect Immun* 1992; 60: 1473–1481.

- 577 [33] Kana IH, Garcia-Senosiaín A, Singh SK, et al. Cytophilic antibodies against key
578 plasmodium falciparum blood stage antigens contribute to protection against clinical
579 malaria in a high transmission region of eastern India. *J Infect Dis*. Epub ahead of print
580 2018. DOI: 10.1093/infdis/jiy258.
- 581 [34] Dobaño C, Santano R, Vidal M, et al. Differential Patterns of IgG Subclass Responses to
582 Plasmodium falciparum Antigens in Relation to Malaria Protection and RTS,S
583 Vaccination. *Front Immunol* 2019; 10: 439.
- 584 [35] Richards JS, Stanisic DI, Fowkes FJI, et al. Association between naturally acquired
585 antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection
586 from malaria and high-density parasitemia. *Clin Infect Dis*; 51. Epub ahead of print 15
587 October 2010. DOI: 10.1086/656413.
- 588 [36] Stanisic DI, Richards JS, McCallum FJ, et al. Immunoglobulin G subclass-specific
589 responses against Plasmodium falciparum merozoite antigens are associated with control
590 of parasitemia and protection from symptomatic illness. *Infection and Immunity* 2009;
591 77: 1165–1174.
- 592 [37] Agnandji ST, Lell B, Fernandes JF, et al. Efficacy and Safety of the RTS,S/AS01
593 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized,
594 Controlled Trial in Children and Young Infants at 11 African Sites. *PLoS Med* 2014; 11:
595 e1001685.
- 596 [38] Dobaño C, Ubbilos I, Jairoce C, et al. RTS,S/AS01E immunization increases antibody
597 responses to vaccine-unrelated Plasmodium falciparum antigens associated with
598 protection against clinical malaria in African children: a case-control study. *BMC Med*
599 2019; 17: 157.
- 600 [39] Sanchez L, Vidal M, Jairoce C, et al. Antibody responses to the RTS,S/AS01E vaccine
601 and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in
602 Mozambique. *npj Vaccines* 2020; 5: 1–16.
- 603 [40] Albrecht P, Ennis FA, Saltzman EJ, et al. Persistence of maternal antibody in infants
604 beyond 12 months: Mechanism of measles vaccine failure. *J Pediatr* 1977; 91: 715–718.
- 605 [41] Halsey NA, Boulos R, Mode F, et al. Response to Measles Vaccine in Haitian Infants 6
606 to 12 Months Old: Influence of Maternal Antibodies, Malnutrition, and Concurrent
607 Illnesses. *N Engl J Med* 1985; 313: 544–549.
- 608 [42] Lee YL, Black FL, Chen CL, et al. The optimal age for vaccination against measles in an
609 asiatic city, Taipei, Taiwan: Reduction of vaccine induced titre by residual transplacental
610 antibody. *Int J Epidemiol* 1983; 12: 340–343.
- 611 [43] Njie-Jobe J, Nyamweya S, Miles DJC, et al. Immunological impact of an additional early
612 measles vaccine in Gambian children: Responses to a boost at 3 years. *Vaccine* 2012; 30:
613 2543–2550.
- 614 [44] Borràs E, Urbiztondo L, Costa J, et al. Measles antibodies and response to vaccination in
615 children aged less than 14 months: Implications for age of vaccination. *Epidemiol Infect*
616 2012; 140: 1599–1606.
- 617 [45] Dobbs KR, DENT AE. Plasmodium malaria and antimalarial antibodies in the first year
618 of life. Cambridge University Press.
- 619 [46] Reynaldi A, Dent AE, Schlub TE, et al. Interaction between maternally derived
620 antibodies and heterogeneity in exposure combined to determine time-to-first
621 Plasmodium falciparum infection in Kenyan infants. *Malar J* 2019; 18: 19.
- 622 [47] González R, Mombo-Ngoma G, Ouédraogo S, et al. Intermittent Preventive Treatment of

623 Malaria in Pregnancy with Mefloquine in HIV-Negative Women: A Multicentre
624 Randomized Controlled Trial. *PLoS Med* 2014; 11: e1001733.

625 [48] González R, Desai M, Macete E, et al. Intermittent Preventive Treatment of Malaria in
626 Pregnancy with Mefloquine in HIV-Infected Women Receiving Cotrimoxazole
627 Prophylaxis: A Multicenter Randomized Placebo-Controlled Trial. *PLoS Med* 2014; 11:
628 e1001735.

629 [49] WHO. *Interim WHO Clinical Staging of HIV/AIDS and HIV/AIDS Case definitions for*
630 *surveillance. African Region*. 2005. Epub ahead of print 2005. DOI:
631 10.1300/j187v04n01_05.

632 [50] Mayor A, Bardají A, Macete E, et al. Changing Trends in *P. falciparum* Burden,
633 Immunity, and Disease in Pregnancy. *N Engl J Med* 2015; 373: 1607–17.

634 [51] González R, Munguambe K, Aponte J, et al. High HIV prevalence in a southern semi-
635 rural area of Mozambique: a community-based survey. *HIV Med* 2012; 13: 581–588.

636 [52] Mayor A, Serra-Casas E, Bardají A, et al. Sub-microscopic infections and long-term
637 recrudescence of *Plasmodium falciparum* in Mozambican pregnant women. *Malar J*
638 2009; 8: 1–10.

639 [53] Gangnard S, Lewit-Bentley A, Dechavanne S, et al. Structure of the DBL3X-DBL4Iε
640 region of the VAR2CSA placental malaria vaccine candidate: Insight into DBL domain
641 interactions. *Sci Rep*; 5. Epub ahead of print 9 October 2015. DOI: 10.1038/srep14868.

642 [54] Persson KEM, Fowkes FJI, McCallum FJ, et al. Erythrocyte-Binding Antigens of
643 *Plasmodium falciparum* Are Targets of Human Inhibitory Antibodies and Function To
644 Evade Naturally Acquired Immunity . *J Immunol* 2013; 191: 785–794.

645 [55] Doolan DL, Hedstrom RC, Rogers WO, et al. Identification and characterization of the
646 protective hepatocyte erythrocyte protein 17 dDa gene of *Plasmodium yoelii*, homolog
647 of *Plasmodium falciparum* exported protein 1. *J Biol Chem* 1996; 271: 17861–17868.

648 [56] Angov E, Aufiero BM, Turgeon AM, et al. Development and pre-clinical analysis of a
649 *Plasmodium falciparum* Merozoite Surface Protein-142 malaria vaccine. *Mol Biochem*
650 *Parasitol* 2003; 128: 195–204.

651 [57] Cavanagh DR, McBride JS. Antigenicity of recombinant proteins derived from
652 *Plasmodium falciparum* merozoite surface protein 1. *Mol Biochem Parasitol* 1997; 85:
653 197–211.

654 [58] Metzger WG, Okenu DMN, Cavanagh DR, et al. Serum IgG3 to the *Plasmodium*
655 *falciparum* merozoite surface protein 2 is strongly associated with a reduced prospective
656 risk of malaria. *Parasite Immunol* 2003; 25: 307–312.

657 [59] Black CG, Barnwell JW, Huber CS, et al. The *Plasmodium vivax* homologues of
658 merozoite surface proteins 4 and 5 from *Plasmodium falciparum* are expressed at
659 different locations in the merozoite. *Mol Biochem Parasitol* 2002; 120: 215–224.

660 [60] Reiling L, Richards JS, Fowkes FJI, et al. The *Plasmodium falciparum* Erythrocyte
661 Invasion Ligand Pfrh4 as a Target of Functional and Protective Human Antibodies
662 against Malaria. *PLoS One* 2012; 7: e45253.

663 [61] Vidal M, Aguilar R, Campo JJ, et al. Development of quantitative suspension array
664 assays for six immunoglobulin isotypes and subclasses to multiple *Plasmodium*
665 *falciparum* antigens. *J Immunol Methods* 2018; 455: 41–54.

666 [62] Ubillos I, Jiménez A, Vidal M, et al. Optimization of incubation conditions of
667 *Plasmodium falciparum* antibody multiplex assays to measure IgG, IgG1–4, IgM and IgE

668 using standard and customized reference pools for sero-epidemiological and vaccine
669 studies. *Malar J*; 17. Epub ahead of print 1 June 2018. DOI: 10.1186/s12936-018-2369-
670 3.

671 [63] Ubillos I, Aguilar R, Sanz H, et al. Analysis of factors affecting the variability of a
672 quantitative suspension bead array assay measuring IgG to multiple Plasmodium
673 antigens. *PLoS One*; 13. Epub ahead of print 1 July 2018. DOI:
674 10.1371/journal.pone.0199278.

675 [64] Bryan D, Silva N, Rigsby P, et al. The establishment of a WHO Reference Reagent for
676 anti-malaria (*Plasmodium falciparum*) human serum. *Malar J*; 16. Epub ahead of print 5
677 August 2017. DOI: 10.1186/s12936-017-1958-x.

678 [65] Ballard JL, Khoury JC, Wedig K, et al. New Ballard Score, expanded to include
679 extremely premature infants. *J Pediatr* 1991; 119: 417–423.

680 [66] Mayor A, Dobaño C, Nhabomba A, et al. IgM and IgG against *Plasmodium falciparum*
681 lysate as surrogates of malaria exposure and protection during pregnancy. *Malar J* 2018;
682 17: 182.

683 [67] Fried M, Kurtis JD, Swihart B, et al. Antibody levels to recombinant VAR2CSA
684 domains vary with *Plasmodium falciparum* parasitaemia, gestational age, and gravidity,
685 but do not predict pregnancy outcomes. *Malar J* 2018; 17: 106.

686 [68] Dobaño C, Berthoud T, Manaca MN, et al. High production of pro-inflammatory
687 cytokines by maternal blood mononuclear cells is associated with reduced maternal
688 malaria but increased cord blood infection. *Malar J* 2018; 17: 177.

689 [69] Wickham H, Hester J, Chang W. devtools: Tools to make developing R packages easier.
690 R package devtools version 2.3.0., <https://cran.r-project.org/package=devtools> (2020,
691 accessed 7 July 2020).

692 [70] Wickham H. ggplot2: Elegant Graphics for Data Analysis. *Springer*.

693 [71] Lê S, Josse J, Husson F. FactoMineR: An R package for multivariate analysis. *J Stat*
694 *Softw* 2008; 25: 1–18.

695 [72] Kassambara A, Mundt F. factoextra: Extract and Visualize the Results of Multivariate
696 Data Analyses. R package version 1.0.7., <https://cran.r-project.org/package=factoextra>
697 (2020).

698 [73] Pou C, Nkulikiyimfura D, Henckel E, et al. The repertoire of maternal anti-viral
699 antibodies in human newborns. *Nat Med* 2019; 25: 591–596.

700 [74] Alonso S, Vidal M, Ruiz-Olalla G, et al. Reduced placental transfer of antibodies against
701 microbial and vaccine antigens in HIV-infected women in Mozambique. *bioRxiv* 2020;
702 2020.08.05.237503.

703 [75] Boudová S, Divala T, Mungwira R, et al. Placental but Not Peripheral *Plasmodium*
704 *falciparum* Infection During Pregnancy Is Associated With Increased Risk of Malaria in
705 Infancy. In: *Journal of Infectious Diseases*. 2017. Epub ahead of print 2017. DOI:
706 10.1093/infdis/jix372.

707 [76] Ismail MR, Ordi J, Menendez C, et al. Placental pathology in malaria: A histological,
708 immunohistochemical, and quantitative study. *Hum Pathol* 2000; 31: 85–93.

709 [77] Sharma L, Shukla G. Placental Malaria: A new insight into the pathophysiology.
710 *Frontiers in Medicine* 2017; 4: 25.

711 [78] Kohler PF, Farr RS. Elevation of Cord over maternal IgG immunoglobulin: Evidence for
712 an active placental IgG transport [39]. *Nature* 1966; 210: 1070–1071.

713 [79] Costa-Carvalho BT, Vieira HM, Dimantas RBR, et al. Transfer of IgG subclasses across
714 placenta in term and preterm newborns. *Brazilian J Med Biol Res* 1996; 29: 201–204.

715 [80] Clements T, Rice TF, Vamvakas G, et al. Update on Transplacental Transfer of IgG
716 Subclasses: Impact of Maternal and Fetal Factors. *Front Immunol* 2020; 11: 1920.

717 [81] Irani V, Guy AJ, Andrew D, et al. Molecular properties of human IgG subclasses and
718 their implications for designing therapeutic monoclonal antibodies against infectious
719 diseases. *Molecular Immunology* 2015; 67: 171–182.

720 [82] Roussilhon C, Oeuvray C, Müller-Graf C, et al. Long-term clinical protection from
721 falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface
722 protein. *PLoS Med* 2007; 4: 1791–1803.

723 [83] Weaver R, Reiling L, Feng G, et al. The association between naturally acquired IgG
724 subclass specific antibodies to the PfRH5 invasion complex and protection from
725 Plasmodium falciparum malaria. *Sci Rep* 2016; 6: 1–10.

726 [84] Reiling L, Richards JS, Fowkes FJI, et al. Evidence That the Erythrocyte Invasion
727 Ligand PfRh2 is a Target of Protective Immunity against Plasmodium falciparum
728 Malaria . *J Immunol* 2010; 185: 6157–6167.

729 [85] Woodberry T, Minigo G, Piera KA, et al. Antibodies to Plasmodium falciparum and
730 Plasmodium vivax merozoite surface protein 5 in Indonesia: Species-specific and cross-
731 reactive responses. *J Infect Dis* 2008; 198: 134–142.

732 [86] Bouharoun-Tayoun H, Druilhe P. Antibodies in falciparum malaria: what matters most,
733 quantity or quality? *Mem Inst Oswaldo Cruz* 1992; 87 Suppl 3: 229–234.

734 [87] Beeson JG, Drew DR, Boyle MJ, et al. Merozoite surface proteins in red blood cell
735 invasion, immunity and vaccines against malaria. *FEMS Microbiology Reviews* 2016;
736 40: 343–372.

737 [88] Duah NO, Miles DJC, Whittle HC, et al. Acquisition of antibody isotypes against
738 Plasmodium falciparum blood stage antigens in a birth cohort. *Parasite Immunol* 2010;
739 32: 125–134.

740 [89] Taylor RR, Allen SJ, Greenwood BM, et al. IgG3 antibodies to Plasmodium falciparum
741 merozoite surface protein 2(MSP2): Increasing prevalence with age and association with
742 clinical immunity to malaria. *Am J Trop Med Hyg* 1998; 58: 406–413.

743 [90] Cavanagh DR, Dodo D, Hviid L, et al. Antibodies to the N-terminal block 2 of
744 Plasmodium falciparum merozoite surface protein 1 are associated with protection
745 against clinical malaria. *Infect Immun* 2004; 72: 6492–6502.

746 [91] Aucan C, Traoré Y, Tall F, et al. High Immunoglobulin G2 (IgG2) and Low IgG4 Levels
747 Are Associated with Human Resistance to Plasmodium falciparum Malaria. *Infect*
748 *Immun* 2000; 68: 1252–1258.

749 [92] Noland GS, Jansen P, Vulule JM, et al. Effect of transmission intensity and age on
750 subclass antibody responses to Plasmodium falciparum pre-erythrocytic and blood-stage
751 antigens. *Acta Trop* 2015; 142: 47–56.

752 [93] Chaudhury S, Regules JA, Darko CA, et al. Delayed fractional dose regimen of the
753 RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum
754 opsonophagocytosis. *Sci Rep*; 7. Epub ahead of print 1 December 2017. DOI:
755 10.1038/s41598-017-08526-5.

756 [94] Cederqvist LL, Ewool LC, Litwin SD. The effect of fetal age, birth weight, and sex on
757 cord blood immunoglobulin values. *Am J Obstet Gynecol* 1978; 131: 520–525.

758 [95] Wesumperuma HL, Perera AJ, Pharoah POD, et al. The influence of prematurity and low
759 birthweight on transplacental antibody transfer in Sri Lanka. *Ann Trop Med Parasitol*
760 1999; 93: 169–177.

761 [96] Okoko BJ, Wesumperuma HL, Fern J, et al. The transplacental transfer of IgG
762 subclasses: Influence of prematurity and low birthweight in the Gambian population.
763 *Ann Trop Paediatr* 2002; 22: 325–332.

764 [97] Ndungu FM, Bull PC, Ross A, et al. Naturally acquired immunoglobulin (Ig)G subclass
765 antibodies to crude asexual *Plasmodium falciparum* lysates: Evidence for association
766 with protection for IgG1 and disease for IgG2. *Parasite Immunol* 2002; 24: 77–82.

767 [98] Goetghebuer T, Smolen KK, Adler C, et al. Initiation of Antiretroviral Therapy Before
768 Pregnancy Reduces the Risk of Infection-related Hospitalization in Human
769 Immunodeficiency Virus-exposed Uninfected Infants Born in a High-income Country.
770 *Clin Infect Dis*. Epub ahead of print 2019. DOI: 10.1093/cid/ciy673.

771 [99] De Milito A, Nilsson A, Titanji K, et al. Mechanisms of hypergammaglobulinemia and
772 impaired antigen-specific humoral immunity in HIV-1 infection. *Blood* 2004; 103:
773 2180–2186.

774 [100] Silveira ELV, Dominguez MR, Soares IS. To B or Not to B: Understanding B Cell
775 Responses in the Development of Malaria Infection. *Frontiers in immunology* 2018; 9:
776 2961.

777 [101] Agudelo OM, Aristizabal BH, Yanow SK, et al. Submicroscopic infection of placenta by
778 *Plasmodium* produces Th1/Th2 cytokine imbalance, inflammation and hypoxia in
779 women from north-west Colombia. *Malar J* 2014; 13: 122.

780 [102] López-Guzmán C, Carmona-Fonseca J. Submicroscopic placental malaria:
781 Histopathology and expression of physiological process mediators. *Rev Peru Med Exp*
782 *Salud Publica* 2020; 37: 220–228.

783

Table 1: Characteristics of study participants.

	All N=341	HIV- N=197	HIV+ N=144	p-value ^a
Age ^a (years median [IQR])	25.0 [19.0; 29.0]	21.0 [18.0; 28.0]	27.0 [22.0; 31.0]	< 0.001
Gravidity (n, %)				< 0.001
<i>Multigravidae</i>	259 (76.0)	128 (65.0)	131 (91.0)	
<i>Primigravidae</i>	82 (24.0)	69 (35.0)	13 (9.0)	
Maternal haemoglobin (n, %)				0.025
Anaemia (< 11 g/dL)	208 (61.5)	109 (56.2)	99 (68.8)	
Normal (≥ 11 g/dL)	130 (38.5)	85 (43.8)	45 (31.2)	
Birth weight (n, %)				1.000
Low (< 2500 g)	29 (8.5)	17 (8.6)	12 (8.33)	
Normal (≥ 2500 g)	312 (91.5)	180 (91.4)	132 (91.7)	
Prematurity (n, %)				0.502
No (≥ 37 weeks)	312 (94.3)	181 (95.3)	131 (92.9)	
Yes (< 37 weeks)	19 (5.7)	9 (4.7)	10 (7.1)	
Treatment				< 0.001
MQ	71 (20.9)	0 (0.0)	71 (49.7)	
MQ full	68 (20.8)	68 (34.5)	0 (0.0)	
MQ split	73 (21.5)	73 (37.1)	0 (0.0)	
Placebo	72 (21.2)	0 (0.0)	72 (50.3)	
SP	56 (16.5)	56 (28.4)	0 (0.0)	
ART (n, %)				NP
No	24 (7.1)	—	24 (17.1)	
Yes	116 (34.4)	—	116 (82.9)	
CD4 ⁺ T cell counts (n, %)				NP
Lower (< 350 c/μL)	40 (12.3)	—	40 (31.2)	
Higher (≥ 350 c/μL)	88 (27.1)	—	88 (68.8)	
HIV viral load (copies/mL)				NP
< 400	21 (6.4)	—	21 (16.0)	
(400–999)	41 (12.5)	—	41 (31.3)	
(1000–9999)	48 (14.6)	—	48 (36.6)	
> 9999	21 (6.4)	—	21 (16.0)	
Placental malaria ^b (n, %)				0.659
No	321 (94.1)	184 (93.4)	137 (95.1)	
Yes	20 (5.9)	13 (6.6)	7 (4.9)	
Peripheral malaria ^c (n, %)				0.531
No	290 (85.0)	165 (83.8)	125 (86.8)	
Yes	51 (15.0)	32 (16.2)	19 (13.2)	

For numerical variables, the median and first and third quantile, in brackets, are given. For the categorical variables the number of individuals for each group and percentages in parentheses, are given.

^a For the age, the Mann-Whitney U test was used to compare differences between median values. For the categorical variables, the Chi-square test was used.

^b Placental malaria was considered positive if there was any evidence of *P. falciparum* placental parasitaemia by any method.

^c Peripheral malaria was considered positive if there was any evidence of *P. falciparum* peripheral parasitaemia by any method.

Statistical significance was considered when *p*-value ≤ 0.05; MQ, mefloquine; NP, not-performed tests; SP, sulfadoxine-pyrimethamine.

Figures

Fig. 1: Overview of cord blood levels of IgG and IgG subclasses to *P. falciparum* antigens for all women. a) Principal component analysis (PCA) plots of cord IgG and IgG subclass levels against all antigens clustered by subclass type. b) PCA plots of cord IgG and IgG subclass levels clustered by antigen type. The two principal components (Dim 1, Dim 2) that explained the highest percentage of the variance of the data (percentage in parenthesis) were chosen for representation. The arrows in a) and b) represent how the variables contribute to each of the two principal components. c) Medians of IgG and IgG subclass levels (log₁₀ MFI) in cord blood for each antigen. d) Medians of IgG and IgG subclass placental transfer for each antigen, represented as the cord/mother ratios.

Fig. 2: Mother and cord blood antibody levels (log₁₀ MFI) in HIV-positive and HIV-negative women and women with PM and without PM. Boxplots illustrate the medians and the interquartile range for IgG in HIV-positive and HIV-negative women (a), IgG in women with PM and women without PM (b), and IgG1, IgG2, IgG3 and IgG4 subclasses in HIV-positive and HIV-negative women (c). Levels between groups were compared by the non-parametric Mann–Whitney U test and p-values were adjusted for multiple testing by the Benjamini–Hochberg approach. Statistically significant differences are highlighted with an asterisk. HIV-positive women are represented in red, HIV-negative women in blue, women with PM in green and women without PM in purple.

Fig. 3: Difference of IgG and IgG subclass levels in cord blood by study factors. Forest plots show the effect (in percentage) of a) maternal antibody levels, b) HIV infection, c) placental malaria and d) low birth weight, on cord blood levels of IgG and IgG subclasses for all the antigens tested. The differences in percentage correspond to beta transformed values (%) that were calculated from the beta values obtained in the multivariable models. Beta transformed values (%) are displayed when raw p-values are significant. Asterisks are shown when adjusted p-values by Benjamini-Hochberg are significant. *** = p-value $\leq$ 0.001, ** = p-value $\leq$ 0.01, * = p-value $\leq$ 0.05.

Fig. 4: Antibody placental transfer in HIV-positive and HIV-negative women. Radar charts representing the medians of each analyte antibody cord/mother ratio in HIV-positive and HIV-negative women for IgG (a) and IgG1 subclass (b). Ratios between HIV-positive and negative women were compared by the non-parametric Mann-Whitney U test and p-values were adjusted for multiple testing by the Benjamini-Hochberg approach. Statistically significant differences between HIV-positive and negative women ratios are highlighted with asterisks. *** = p-value ≤ 0.001 , ** = p-value ≤ 0.01 , * = p-value ≤ 0.05 . HIV-positive women are represented in red and HIV-negative women in blue.

830

831

Fig. 5: Difference of IgG and IgG subclass placental transfer by study factors. Forest plots show the effect (in percentage) of a) HIV infection, b) placental malaria and c) low birth weight, on placental transfer of IgG and IgG subclasses for all the antigens tested. The differences in percentage correspond to beta transformed values (%) that were calculated from the beta values obtained in the multivariable models. Beta transformed values (%) are displayed when raw p-values are significant. Asterisks are shown when adjusted p-values by Benjamini-Hochberg are significant. *** = p-value ≤ 0.001 , ** = p-value ≤ 0.01 , * = p-value ≤ 0.05 .

839